All Legal Tryptamines 2026: Comparison Table

Several 4-substituted tryptamines are still legally purchasable in Germany as of April 2026. They sit outside both BtMG individual listings and NpSG structural group definitions. This table breaks down every available tryptamine research chemical – 4-Pro-MET, 4-PrO-DMT, and others – covering effects profiles, dosage ranges, durations, and legal classifications across the DACH region. It's the question I get asked most in the research community, so let's get into it.

Germany runs a dual-track system. The BtMG lists individual compounds; the NpSG defines banned structural groups. Here's the detail that matters: the NpSG's tryptamine definition requires a 2-(1H-indol-3-yl)-2-oxoethyl base structure. Compounds with a simple 2-aminoethyl side chain don't match. So 4-Pro-MET and several other 4-substituted tryptamines sit outside NpSG jurisdiction entirely.

The BtMG works differently. It schedules compounds one by one: psilocybin, psilocin, DMT, 5-MeO-DMT, and 4-AcO-DMT (added 2022) are all listed. But it can't cover every variant. Approximately 85% of tryptamine derivatives remain unscheduled under the BtMG as of early 2026.

This table includes only compounds believed to be legal in Germany as of April 2026. Legal status can change at any time through BtMG amendments or NpSG updates. Always verify current regulations before purchasing.

The European research chemical market looks nothing like 2016, when the NpSG first took effect. Vendors adapted. As familiar compounds got scheduled, structural variants that sit outside existing definitions filled the gap. 4-Pro-MET appeared in August/September 2025 as part of this pattern – and it's gaining traction. Propionyloxy tryptamines combine legal availability, stability, and pharmacological profiles linked to well-known compounds like psilocybin.

The numbers speak for themselves. The EMCDDA (now EUDA) Early Warning System reported over 50 new synthetic compounds entering the European market in 2025 alone. For tryptamines specifically, the trend points toward ester prodrugs with increasingly diverse acyl chains – past the acetyloxy series into propionyloxy, butyryloxy, and beyond.